ORUKA THERAPEUTICS INC (ORKA) Fundamental Analysis & Valuation

NASDAQ:ORKA • US6876041087

34.99 USD
+2.15 (+6.55%)
At close: Mar 4, 2026
34.99 USD
0 (0%)
After Hours: 3/4/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ORKA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ORKA. ORKA was compared to 520 industry peers in the Biotechnology industry. ORKA has a great financial health rating, but its profitability evaluates not so good. ORKA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. ORKA Profitability Analysis

1.1 Basic Checks

  • In the past year ORKA has reported negative net income.
  • In the past year ORKA has reported a negative cash flow from operations.
  • ORKA had negative earnings in each of the past 5 years.
  • ORKA had a negative operating cash flow in each of the past 5 years.
ORKA Yearly Net Income VS EBIT VS OCF VS FCFORKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -19.96%, ORKA is in the better half of the industry, outperforming 75.77% of the companies in the same industry.
  • ORKA's Return On Equity of -20.88% is amongst the best of the industry. ORKA outperforms 81.92% of its industry peers.
Industry RankSector Rank
ROA -19.96%
ROE -20.88%
ROIC N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ORKA Yearly ROA, ROE, ROICORKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • ORKA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORKA Yearly Profit, Operating, Gross MarginsORKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ORKA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ORKA has more shares outstanding
  • The number of shares outstanding for ORKA has been increased compared to 5 years ago.
  • There is no outstanding debt for ORKA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORKA Yearly Shares OutstandingORKA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ORKA Yearly Total Debt VS Total AssetsORKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ORKA has an Altman-Z score of 44.83. This indicates that ORKA is financially healthy and has little risk of bankruptcy at the moment.
  • ORKA has a better Altman-Z score (44.83) than 95.19% of its industry peers.
  • There is no outstanding debt for ORKA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 44.83
ROIC/WACCN/A
WACCN/A
ORKA Yearly LT Debt VS Equity VS FCFORKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 16.94 indicates that ORKA has no problem at all paying its short term obligations.
  • ORKA's Current ratio of 16.94 is amongst the best of the industry. ORKA outperforms 93.27% of its industry peers.
  • A Quick Ratio of 16.94 indicates that ORKA has no problem at all paying its short term obligations.
  • ORKA's Quick ratio of 16.94 is amongst the best of the industry. ORKA outperforms 93.27% of its industry peers.
Industry RankSector Rank
Current Ratio 16.94
Quick Ratio 16.94
ORKA Yearly Current Assets VS Current LiabilitesORKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ORKA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 66.48% over the past year.
EPS 1Y (TTM)66.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ORKA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.48% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.65%
EPS Next 2Y11.73%
EPS Next 3Y5.34%
EPS Next 5Y-2.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORKA Yearly Revenue VS EstimatesORKA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 500M 1B 1.5B
ORKA Yearly EPS VS EstimatesORKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

0

4. ORKA Valuation Analysis

4.1 Price/Earnings Ratio

  • ORKA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORKA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORKA Price Earnings VS Forward Price EarningsORKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORKA Per share dataORKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.73%
EPS Next 3Y5.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ORKA Dividend Analysis

5.1 Amount

  • ORKA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORKA Fundamentals: All Metrics, Ratios and Statistics

ORUKA THERAPEUTICS INC

NASDAQ:ORKA (3/4/2026, 8:00:03 PM)

After market: 34.99 0 (0%)

34.99

+2.15 (+6.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-05
Inst Owners92.65%
Inst Owner Change11.93%
Ins Owners2.94%
Ins Owner Change21.93%
Market Cap1.69B
Revenue(TTM)N/A
Net Income(TTM)-101.63M
Analysts88
Price Target57.98 (65.7%)
Short Float %8.95%
Short Ratio7.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.61%
Min EPS beat(2)7.26%
Max EPS beat(2)7.96%
EPS beat(4)4
Avg EPS beat(4)16.82%
Min EPS beat(4)7.26%
Max EPS beat(4)29.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.73%
PT rev (3m)21.66%
EPS NQ rev (1m)1.67%
EPS NQ rev (3m)4.71%
EPS NY rev (1m)0%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.48
P/tB 3.48
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.61
Fwd EYN/A
FCF(TTM)-1.75
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0
BVpS10.06
TBVpS10.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.96%
ROE -20.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 230.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.94
Quick Ratio 16.94
Altman-Z 44.83
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)236.67%
Cap/Depr(5y)235.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.33%
EPS Next Y36.65%
EPS Next 2Y11.73%
EPS Next 3Y5.34%
EPS Next 5Y-2.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-69.28%
EBIT Next 3Y-30.23%
EBIT Next 5YN/A
FCF growth 1Y-1451.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1448.68%
OCF growth 3YN/A
OCF growth 5YN/A

ORUKA THERAPEUTICS INC / ORKA FAQ

Can you provide the ChartMill fundamental rating for ORUKA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ORKA.


What is the valuation status for ORKA stock?

ChartMill assigns a valuation rating of 0 / 10 to ORUKA THERAPEUTICS INC (ORKA). This can be considered as Overvalued.


What is the profitability of ORKA stock?

ORUKA THERAPEUTICS INC (ORKA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ORUKA THERAPEUTICS INC?

The Earnings per Share (EPS) of ORUKA THERAPEUTICS INC (ORKA) is expected to grow by 36.65% in the next year.